NCT07156058View on ClinicalTrials.gov

MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer

NARecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Biliary Tract Cancer
Interventions
OTHER

MiniPDX group

Personalized treatment for guided by mini-PDX. The MiniPDX test can provide drug sensitivity results in as little as 7 days. Drugs including but not limited to the following agents: capecitabine, gemcitabine + cis-platinum, gemcitabine + capecitabine, 5-FU + oxaliplatin, gemcitabine, 5-FU, capecitabine + cis-platinum, 5-FU + cis-platinum.

DRUG

Capecitabine

Drug: Capecitabine

Trial Locations (1)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER